Viewing Study NCT01671332


Ignite Creation Date: 2025-12-24 @ 9:56 PM
Ignite Modification Date: 2026-01-05 @ 6:26 PM
Study NCT ID: NCT01671332
Status: COMPLETED
Last Update Posted: 2020-05-12
First Post: 2012-06-25
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer
Sponsor: University of Wisconsin, Madison
Organization:

Study Overview

Official Title: Randomized Phase II Study of Suramin and Docetaxel Versus Docetaxel in Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy
Status: COMPLETED
Status Verified Date: 2020-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.
Detailed Description: The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second and third line settings.

Secondary objectives include:

* To compare response rate of patients in both treatment arms
* To compare overall survival of patients in both treatment arms
* To compare toxicity in both treatment arms
* To determine whether the survival benefit from suramin is associated with reduced M-phase entry in peripheral blood lymphocytes

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
A534260 OTHER UW Madison View
SMPH/MEDICINE/MEDICINE*H OTHER UW Madison View
2012-0118 OTHER Institutional Review Board View
NCI-2012-01113 REGISTRY NCI Trial ID View